Hewmun Lau

Hewmun Lau, MBA, is a Principal at Broadview Ventures.

Hewmun shares responsibility for the day-to-day investment activities at Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement.

Hewmun comes to Broadview with 10 years of life science experience across business development, commercial operations, consulting and R&D. Previously, Hewmun was at Merrimack Pharmaceuticals where she held several roles with increasing responsibility. She was most recently Director of Corporate Development where she led the company’s business development activities. Her prior positions within Merrimack include Associate Director of New Product Planning and Senior Manager of Commercial Analytics where she supported the launch of Merrimack’s first marketed drug. Before Merrimack, Hewmun was a Senior Consultant at Navigant Consulting’s Life Sciences Practice. At Navigant, she worked on engagements involving big pharma and emerging biotech companies across all therapeutic areas. Client engagements ranged from commercial opportunity assessment to launch strategy and product lifecycle management. Hewmun began her career in biomedical research including lab research positions at Millennium Pharmaceuticals and McLean Hospital.

Hewmun holds a B.S. in Biochemistry, Biology and Economics Cum Laude from Brandeis University, an MBA from MIT’s Sloan School of Management and a M.S. from the Harvard-MIT Program in Health Sciences and Technology.

Hewmun currently holds board roles at Basking Biosciences (Observer), Antag Therapeutics (Observer), Renovacor (Observer), and ZZ Biotech (Observer).